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ABSTRACT
What should not be patentable? The Agreement on Trade-Related Aspects of Intellectual Property
Rights (“TRIPS”) codifies certain categories of subject matter that nations can exclude from patent
protection. This Article examines how nations have interpreted these exclusions through an analysis
of their national manuals of patent examining procedure and more importantly what explicit
exceptions to patentability these countries have listed. The Article proceeds to analyze both the
similarities and differences in approaches towards exclusions that attempt to ban the same subject
matter from patentability and differences in what countries have chosen to bar from patenting. The
Article concludes with an argument for a harmonization of the international patent regime, noting
how some countries have taken substantial liberties with the TRIPS language.
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NATIONALIZING TRIPS: AN EXAMINATION THROUGH EXCEPTIONS
EVAN H. TALLMADGE*
I. INTRODUCTION
What can be patented? What shouldn’t be patentable? Where and how should
countries draw these lines? These are some of the central questions of national policy
debates in trying to incentivize innovation with the patent system.1 Over the last
hundred years,2 the international community has been moving towards answering this
among other important questions of national patent policy, and some consensus has
developed over what things shouldn’t be patentable. The outlines of an international
standard of patentability were codified in the Agreement on Trade-Related Aspects of
Intellectual Property Rights (“TRIPS”) Article 273 and incorporated into the national
law and regulations of members of the World Trade Organization (“WTO”).4 Each
member nation of the WTO is responsible for implementing TRIPS into their own
national laws,5 and different WTO member states have decided differently on the
questions of what is eligible subject matter and what should explicitly excluded from
patentability in their national implementation of TRIPS.
Until the late 19th century, patent law was an entirely national affair.6 In 1883
eleven countries signed the Paris Convention for the Protection of Industrial Property,
the first major multilateral international intellectual property treaty.7 In the
negotiations leading up to the Paris Convention proposals were considered for a
substantially harmonized international patent system, but due to major differences in
national patent law these proposals were not incorporated into the final treaty.8 The
Paris Convention did establish a set of basic principles for the grant of intellectual
property and a process by which individuals could more easily apply for patents in all
of the national patent offices of the member states.9 This desire for patent
harmonization, both procedural and substantive, led to additional treaties and the

* © Evan H. Tallmadge 2019.
J.D., Harvard Law School, 2018; Ph.D., Chemistry, Cornell
University, 2015. I would like to thank Prof. Ruth Okediji for her indispensable mentorship and
guidance on this paper.
1 See, e.g., Andrew Beckerman-Rodau, What Should Be Patentable - A Proposal for Determining
the Existence of Statutory Subject Matter under 35 U.S.C. Section 101, 13 WAKE FOREST J. BUS. &
INTELL. PROP. L. 145 (2013).
2 About WIPO, World Intellectual Property Organization, http://www.wipo.int/aboutwipo/en/history.html (last visited Mar. 27, 2019).
3 Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, Apr. 15, 1994,
1869 U.N.T.S. 154, 33 I.L.M. 1144 [hereinafter TRIPS].
4 TRIPS Art. 1.
5 Id.
6 E. Wyndham Hulme, On the History of Patent Law in the Seventeenth and Eighteenth Centuries,
18 L. Q. REV. 280, 280 (1902).
7 MARGO A. BAGLEY, RUTH L. OKEDIJI, & JAY A. ERSTLING, INTERNATIONAL PATENT LAW AND
POLICY 3 (1st ed. 2013)
8 Id.
9 Id.
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eventual establishment of the World Intellectual Property Organization (“WIPO”).10
Although WIPO strove for the “development of a balanced and effective international
intellectual property (IP) system that enables innovation and creativity for the benefit
of all,”11 there was a substantial conflict between what developed and developing
countries viewed as “balanced and effective.”12 The developed countries, faced with this
conflict, decided to shift the forum of the debate to the General Agreement on Tariffs
and Trade (“GATT”).13 Developing countries, dependent on the access to developed
countries’ markets GATT provided, acceded to this transition.14 In 1986, the Uruguay
Round of trade negotiations began under the aegis of GATT.15
After seven years, the Uruguay Round of trade negotiations produced TRIPS, and
saw the replacement of GATT with the WTO.16 TRIPS mandated minimum protection
for intellectual property from the member countries of the WTO, enforced by trade
sanctions.17 Participation in TRIPS was incentivized by the trade benefits of joining
the WTO, a powerful lure for developing countries who would otherwise have not
agreed to more stringent intellectual property protections.18
TRIPS covered copyrights, patents, and trademarks and established standards.
TRIPS Article 27 defines what categories of subject matter WTO member countries
must grant patents on, stating:
1. Subject to the provisions of paragraphs 2 and 3, patents shall be available
for any inventions, whether products or processes, in all fields of technology,
provided that they are new, involve an inventive step and are capable of
industrial application. [For the purposes of this Article, the terms “inventive
step” and “capable of industrial application” may be deemed by a Member to
be synonymous with the terms “non-obvious” and “useful” respectively.]
Subject to paragraph 4 of Article 65 [transitional arrangement which allow
developing countries to delay implementation], paragraph 8 of Article 70
[transitional structure for countries who do not initially have available
pharmaceutical and agricultural chemical products patents] and paragraph
3 of this Article, patents shall be available and patent rights enjoyable

10
About WIPO, World Intellectual Property Organization, http://www.wipo.int/aboutwipo/en/history.html (last visited Mar. 27, 2019).
11 Id.
12 BAGLEY ET AL., supra note 7, at 3.
13 Id. at 4.
14 Timothy Geithner & Gobind Nankani, Market Access for Developing Country Exports —
Selected Issues 4–7 (Sept. 26, 2002), https://www.imf.org/external/np/pdr/ma/2002/eng/092602.pdf.
15 The Uruguay Round, WTO, https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact5_e.htm
last visited Mar. 27, 2019).
16 Id.
17 TRIPS Art. 64; see also Historic Development of the WTO Dispute Settlement System, WTO,
https://www.wto.org/english/tratop_e/dispu_e/disp_settlement_cbt_e/c2s1p1_e.htm (last visited Mar.
27, 2019).
18 Ruth L. Okediji, The International Relations of Intellectual Property: Narratives of Developing
Country Participation in the Global Intellectual Property System, 7 SING. J. INT’L & COMP. L. 315, 323–
325 (2003).
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without discrimination as to the place of invention, the field of technology
and whether products are imported or locally produced.
2. Members may exclude from patentability inventions, the prevention
within their territory of the commercial exploitation of which is necessary to
protect ordre public or morality, including to protect human, animal or plant
life or health or to avoid serious prejudice to the environment, provided that
such exclusion is not made merely because the exploitation is prohibited by
their law.
3. Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the treatment of humans
or animals;
(b) plants and animals other than micro-organisms, and essentially
biological processes for the production of plants or animals other than nonbiological and microbiological processes. However, Members shall provide for
the protection of plant varieties either by patents or by an effective sui
generis system or by any combination thereof. The provisions of this
subparagraph shall be reviewed four years after the date of entry into force
of the WTO Agreement.19
TRIPS thus has standardized how members must address the question of whether to
grant a patent by setting up three general barriers to patentability: (1) is there a claim
to an “invention;” (2) is that invention of a character to be “worth to the public the
embarrassment of an exclusive patent;”20 and (3) is that “patentable invention” subject
matter in a class of inventions explicitly excluded from patentability.
Within answering the question of if there is a claim to an invention, there is one
expressed hurdle to patentability: the claimed subject matter must be within an
acceptable category of invention — a product or process. Different countries have
nationalized this requirement slightly differently: from South Korea’s “highly
advanced creation of a technical idea using the rules of nature”21 to the United State’s
“process, machine, manufacture, or composition of matter.”22 Countries generally agree
that there is some subject matter that, even if novel and nonobvious, is inherently
outside what society thinks of as an “invention.” The most common example of this is
the discovery of a natural law: neither the photoelectric effect nor E=mc2 could ever
have been monopolized by Einstein under patent. “Such discoveries are
‘manifestations of . . . nature, free to all men and reserved exclusively to none”23 and
thus outside of the patent system’s reach entirely. Therefore, under TRIPS a patent
cannot be denied on the basis that the subject matter is in a certain area of technology
TRIPS Art. 27.
Letter from Thomas Jefferson to Isaac McPherson, (Aug. 13, 1813), (on file with the
University of Chicago Law School Library), http://presspubs.uchicago.edu/founders/documents/a1_8_
8s12.html (last visited Mar. 27, 2019).
21Patent Act, Article 2(1) (S. Kor.) http://www.kipo.go.kr/upload/en/download/PatentAct.pdf (last
visited Mar. 27, 2019).
22 35 U.S.C. § 101 (2012).
23 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
19
20
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and is therefore not an “invention.” A patent may be denied though if the claimed
subject matter is not to a product or process, such as a propagating electromagnetic
signal.
An important addition to these exclusions given the debate in the legal world
around the intellectual property protection for computer programs:24 computer
programs are offered protection under copyright, and not under patent according to
TRIPS.25 Most countries have chosen to rule that computer programs are neither a
process nor a product, and thus are not in an acceptable category of invention,
rendering them not an “invention” and thus not patentable.26
Even if the claim passes the first hurdle and can thus be thought of as an
“invention,” some inventions are not “patentable inventions” because the cost of
granting a monopoly gains society nothing in return. To qualify as a “patentable
invention, the claimed subject matter must be new, involve an inventive step (known
as non-obviousness invention in American patent parlance),27 and it must be capable
of industrial application (the useful criteria in American patent law).28 If a patent was
granted on known, obvious, or non-useful inventions, society would not be getting the
benefit of the bargain of the patent system, exchanging a monopoly for nothing. TRIPS
recognizes this essential tradeoff and countries have nationalized these requirements
in differing, albeit similar ways.
If the claimed subject matter passes the aforementioned two hurdles, it can be
thought of as a “patentable invention.” However, even if there is a claim to an
invention, a patent may not be issued if the invention is covered by one of the
exceptions listed in TRIPS 27(2) and (3) if a nation chooses to incorporate them into its
national law.29 As a matter of public policy, some countries do not want to grant
incentives for innovation into areas which are so offensive to public morality such as
human cloning, or to grant monopolies on the essential life-saving skills of doctors.
TRIPS thus allows national governments to exclude narrow categories of otherwise
patentable inventions from patentability if the nation decides to do so. These three
hurdles to patentability — invention, patentable invention, and public policy
exclusions — form the baseline of intellectual property protection for all WTO
countries.
TRIPS Article 27 gives countries significant flexibility in crafting their national
laws to be in compliance with the three hurdles. What constitutes an inventive step?
How offensive must an invention be to be denied patent protection – would a machine
who’s only function was to make a farting sound count, or should the standard be set
to only bar methods of brutally massacring human beings?30 Is it in a country’s best
interest to grant patents on animal-focused surgical methods? If so, that country may
24 See, e.g., Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014); Oracle Am., Inc. v. Google
Inc., 750 F.3d 1339 (Fed. Cir. 2014).
25 TRIPS Art. 10 (“Computer programs, whether in source or object code, shall be protected as
literary works under the Berne Convention”).
26 See, e.g., USPTO, MANUEL OF PATENT EXAMINING AND PROCEDURE § 2106 (9th ed. 2017) (last
revised Jan. 2018) [hereinafter MPEP]; Gottschalk v. Benson, 409 U.S. 63, 72 (1972).
27 TRIPS Art. 27.
28 Id.
29 Id.
30 Compare Japanese public morality exception to Indian public morality exception, infra Section
III.E.1.

[18:285 2019]

Nationalizing TRIPS:
An Examination Through Exceptions

291

choose to not nationalize the exception to animal diagnostic, therapeutic, and surgical
methods, but retain the exception with regards to human methods.31 This voluntary
nature of the exceptions has resulted in a patchwork of national laws and regulations.32
In addition, although TRIPS obligates member states to have written patent laws33
that meet the minimum specifications of patentability in Article 27, TRIPS does not
bar higher standards of patentability so long as they are not applied in a
discriminatory manner.34 This results in a patchwork of standards for novelty,
nonobviousness, and usefulness.35 These heightened standards can be used as sources
of exceptions, as a country could determine that a product that exists in nature is not
novel.36 This Article argues that the next multilateral intellectual property treaty
should seek to harmonize these exceptions in order to promote the goal of a unified
world patent system.
This Article looks at what specific technologies or categories of subject matter
national patent offices have explicitly excluded from patentability. The primary
sources of information used in this Article are the national manuals of patent
examining procedure which serve as a unified reference of laws, legal judgments, and
agency regulations. There are many claims to subject matter or inventions which may
not be patentable, but this Article focuses only on those which have warranted
inclusion as “expressly excluded from patentability.”37 Different patent offices have
chosen to provide very different levels of detail in their lists of exclusions. Despite these
limitations, this paper attempts to extract some insight into “what’s in and what’s
out”38 and argue for harmonizing these exclusions in an attempt to move towards a
unified international patent system.
The focus of this Article is on the explicitly listed exclusions to patentability in
each patent office, and specifically on examples these patent offices provide to
illustrate these exclusions. Unlike the standards for novelty, nonobviousness, and
usefulness, explicit exclusions provide bright lines upon which a policy decision has
been made. This is useful for the outside researcher because it allows for direct
comparisons of subject matter across national patent offices with some definiteness, as
opposed to the unsatisfying debate as to whether an invention is nonobvious under the
imprecise standards of each office. This Article will leverage this definiteness to see
how various patent offices draw lines in the sand for determining patentability in light
of TRIPS Article 27. This bright-line approach to analysis is also useful for determining
compliance, as these exceptions to patentability can be directly measured against
TRIPS mandates irrespective of the actual practice of the national patent office.

See, e.g., Section II.D.3.
See infra, Part III.
33 See India — Patent Protection for Pharmaceutical and Agricultural Chemical Products, WTO
DS50 (Apr. 28, 1999), https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds50_e.htm.
34 See TRIPS Art. 1(3).
35 See infra, Part III.
36 See infra, Section III.B.
37 How to Get a European Patent: Guide for Applicants, EPO, ¶28 (18th ed. 2018),
http://documents.epo.org/projects/babylon/eponet.nsf/0/8266ED0366190630C12575E10051F40E/$Fil
e/how_to_get_a_european_patent_2018_en.pdf (last visited Mar. 27, 2019).
38 Mark P. McKenna & Christopher Jon Sprigman, What’s In, and What’s Out: How IP’s Boundary
Rules Shape Innovation, 30 HARV. J.L. & TECH. 491 (2017).
31
32
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An important aside to this discussion is what constitutes compliance with
international law. If the laws of the country are in compliance with TRIPS, is the
country in compliance if the regulations of the patent office exclude inventions from
patentability that go beyond what TRIPS allows? Is the country in compliance if the
regulations of the patent office are TRIPS compliant, but the practice of the office is
not? This is a deeply contested debate among academic circles,39 and will not be
explored in detail here. However, given the focus of this Article is on the written
regulations of national patent offices, hereinafter compliance with TRIPS will be
viewed as a comparison between the written mandates of TRIPS and the written
regulations of each national patent office. The actual practice of patent offices in
enforcing their own regulations and not going beyond the listed prohibitions to
patentability is beyond the ambit of this Article.
As a matter of background, the reader should be familiar with the ideas of novelty,
nonobviousness, and utility upon which many of the following exceptions are based. At
the core, the patent bargain is a trade of monopoly power for disclosure of an invention
to society.40 In light of past instances where monopoly power was handed out as a
government prerogative as a reward to backers and influencers,41 nations have codified
this patent bargain to include some qualifiers for what needs to be disclosed to make
the monopoly worth it to society. These qualifiers are novelty, nonobviousness, and
utility. They serve to narrow the field of inventions which qualify for the grant of
monopoly to those society does not already have access to.42 In general, novelty requires
that the invention has not been made available to the public before.43 Nonobviousness
generally requires that, even if the invention has not been described in its claimed
form or otherwise available to the public, it is not a mere trivial variation on something
that is already available.44 Utility generally requires that the invention have some
known use that is disclosed, preventing speculative patents where monopoly is granted
on some substance without the corresponding benefit to society of the knowledge of
what that substance does.45 Each country has nationalized these requirements for
patentability slightly differently, but the general requirements are the same even if
the exact level of novelty or nonobviousness required to qualify for a patent are
different. These general requirements form the groundwork upon which many of the
aforementioned exclusions to patentability are based, and so reference should be made
to the national requirements for these categories when analyzing the exceptions.
This Article will examine the manuals of patent examining procedure from
Canada, the EPO, India, Japan, South Korea, Singapore, and the United States. These
countries were chosen for study for a variety of reasons: WIPO has English translations
39 See, e.g., Benedict Kingsbury, The Concept of Compliance as a Function of Competing
Conceptions of International Law, 19 MICH. J. INT'L L. 345 (1998); Joel P. Trachtman, International
Law and Domestic Political Coalitions: The Grand Theory of Compliance with International Law, 11
CHI. J. INT. L. 127 (2010).
40 Shubha Ghosh, Patents and the Regulatory State: Rethinking the Patent Bargain Metaphor
After Eldred, 19 BERKELEY TECH. L.J. 1315, 1315 (2004).
41 Blackstone’s Commentaries on the Laws of England, YALE, http://avalon.law.yale.edu/18th_ce
ntury/blackstone_bk2ch21.asp (last visited Mar. 27, 2019).
42 WILLIAM MARTIN, THE ENGLISH PATENT SYSTEM 74 (1st ed. 1904).
43 See, e.g., MPEP § 2131.
44 See, e.g., Id. § 2141.
45 See, e.g., Id. § 2107.
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of their manuals of patent examining procedure,46 the selected countries have detailed
manuals and not more general guidelines,47 and they represent a broad swath of the
world within the preceding two categories. Since the EPO was studied, no manuals of
patent examining procedure from its constituent countries were included in this
analysis, even though there is a very interesting dynamic between the EPO and each
national patent office.48
Part II of the Article details the regulations concerning exclusions of patentability
from the aforementioned selection of national patent offices. Part III examines the
commonalities and differences between these national regulations and compares them
to the mandates of TRIPS. Part IV concludes this article with an analysis of areas of
patentability still in dispute between nations, and suggests reasonable compromises
in light of the trend towards a unified international patent system.
II. NATIONAL PATENT REGULATIONS ON PATENTABILITY
A. Regulations of the Canadian Intellectual Property Office
Section 12.03 of the Canadian Manual of Patent Office Practice lists nine
categories of subject matter excluded from patentability.49 It includes exclusions of
patentability under theories that the subject matter doesn’t satisfy the requirements
to be an invention, that the invention is not industrially applicable, and that the
invention is against public morality. It does not contain statutory exclusions under the
theories of novelty or nonobviousness. Of note, Canada categorizes many of its listed
exclusions under the theory of industrial inapplicability, such as the exclusion on
aesthetic creations, whereas many other nations treat similar subject matter as not an
invention.
1. Categories of Invention
The Canadian Manual of Patent Office Practice excludes scientific principals and
abstract ideas from patentability as they are not statutory subject matter.50 Subject
matter that fits under this section is mathematical formulae, natural phenomena, and
laws of nature. General claims to such intangible subject matter are unpatentable, but
the office does not exclude claims that rely upon the idea or principal in operating a
practical form of the invention.51
46 Guidelines and Manuals of National / Regional Patent Offices, WIPO, http://www.wipo.int/pa
tents/en/guidelines.html (last visited Mar. 27, 2019).
47 See, e.g., Patents, CZECH INDUSTRIAL PROPERTY OFFICE, http://www.upv.cz/en/iprights/patents.html (last visited Mar. 27, 2019).
48 The Unitary Patent and Unified Patent Court, UNITED KINGDOM INTELL. PROP. OFF. (May 22,
2014), https://www.gov.uk/guidance/the-unitary-patent-and-unified-patent-court.
49 CANADIAN INTELLECTUAL PROPERTY OFFICE, MANUAL OF PATENT OFFICE PRACTICE §12.03
(Can.) (2017).
50 Id. § 12.03.01.
51 Id.
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The Canadian Intellectual Property Office also excludes forms of energy such as
electromagnetic or acoustic signals from patentability on the basis that they are not
inventions.52 The office states that electromagnetic waves fit neither the definition of
process nor the definition of a composition of matter, even though electromagnetic
waves are a mode by which a physical effect is produced, the traditional definition of
process.53
2. Industrial Application
Canadian patent law approaches the TRIPS criteria of Industrial Application is
by requiring that inventions solve a practical problem.54 Inventions that do not solve a
practical problem are thus not patentable in Canada.
Features of solely intellectual or aesthetic significance are not patentable
inventions,55 nor are printed matter generally.56 This is because aesthetic features
“cannot change the manner in which the practical form of an invention operates to
solve the problem for which it is the solution.”57 However, if a printed matter is useful
in more than the aesthetic sense it is patentable,58 such as printing on textiles to allow
greater precision in the manufacturing process.59
Likewise, fine arts such as “exercising, dancing, acting, writing, teaching, hair
dressing, cosmetology, flower arranging, painting pictures and playing musical
instruments” are not patentable inventions.60 Since these inventions do not solve a
practical problem, they are considered outside of the scope of patentability.
Schemes, plans, rules, and mental processes are not patentable inventions.61 The
office states that because these categories of inventions are disembodied, they are not
a practical form of invention.62
3. TRIPS Article 27(2) & (3) Exclusions
The Canadian Patent Office explicitly excludes methods of medical treatment on
living humans or animals from patentability.63 Any method which provides a practical
therapeutic benefit to a subject is not patentable, even if this benefit is not the method’s
primary or even intended purpose.64 The office sets the definition of therapeutic benefit
as “the method should cure, prevent or ameliorate an ailment or pathological condition,

Id. § 12.03.04.
Id.
54 Id. § 9.03.
55 Id. § 12.03.05.
56 Id. § 12.03.06.
57 Id. § 12.03.05.
58 Id. § 12.03.06 (printed matter provided a new mechanical functionality to the combination).
59 Id.
60 Id. § 12.03.07.
61 Id. § 12.03.08.
62 Id.
63 Id. § 12.03.02.
64 MANUAL OF PATENT OFFICE PRACTICE §12.03 (Can.) (2017).
52
53
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or treat a physical abnormality or deformity such as by physiotherapy or surgery.”65
Excluded from this are natural conditions, including ageing, pregnancy, baldness, and
wrinkles which are not considered pathological, and thus patents on methods to treat
these conditions are allowed.66 All methods of surgery, therapeutic or not, are excluded.
The office states that certain noninvasive methods of diagnosing a disease or medical
condition either in vitro or in vivo are patentable. The Office clarifies that these
methods are patentable so long as there is no secondary therapeutic benefit. Treating
an animal solely to derive an economic benefit or methods for achieving a cosmetic
result may not be excluded from patentability on a per se basis.67
Canada excludes higher life forms from patentability on the basis that higher life
forms are not inventions,68 but TRIPS allows this exclusion under Article 27(3)(b).
Higher life forms are defined as multicellular life,69 and are excluded from
patentability because they are not compositions of matter or manufactures and so are
not considered inventions.70 The designation of a higher life form is applicable at any
stage of development, so fertilized eggs and totipotent stem cells are excluded from
patentability.71 Organs and tissues are generally not patentable.72 However, a cell
which is not alone capable of development into an organism is not considered a higher
life form, so embryonic, multipotent, and pluripotent cell lines are patentable.73
B. Regulations of the European Patent Office
The European Patent Office only provides two classes of unpatentable subject
matter: subject matter that does not qualify as an “invention” and subject matter that
offends public morality.
1. Categories of Invention
The European Patent Office does not provide a definition for invention, but does
provide a non-exhaustive list of inventions which it does not consider inventions.74
Given examples are “(a) discoveries, scientific theories and mathematical methods; (b)
aesthetic creations; (c) schemes, rules and methods for performing mental acts, playing
games or doing business, and programs for computers; (d) presentations of
information.”75

Id.
Id.
67 Id.
68 Id. § 12.03.03.
69 Id. § 17.02.01.
70 Id. § 12.03.03.
71 Id. § 17.02.01.
72 Id. § 17.02.02.
73 Id.
74 How to Get a European Patent: Guide for Applicants, EPO, ¶28 (18th ed. 2018), http://documen
ts.epo.org/projects/babylon/eponet.nsf/0/8266ED0366190630C12575E10051F40E/$File/how_to_get_a
_european_patent_2018_en.pdf (last visited Mar. 27, 2019).
75 EUROPEAN PATENT OFFICE, EUROPEAN PATENT CONVENTION Art. 52(2) (16th ed. 2016) (Eur.).
65
66
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Computer programs are not regarded as inventions if claimed as such. This is
immaterial to whether the program is claimed by itself, as a data medium storing
system, or a part of a computer system.76 However, computer programs are patentable
if, when running on a computer, the program causes a further technical effect going
beyond the normal physical interaction between software and hardware such as a
program that serves to control a technical process or governs the operation of a
technical device. This added functionality is considered sufficiently inventive to
warrant a patent.
2. TRIPS Article 27(2) & (3) Exclusions
Methods for treatment of the human or animal body by surgery or therapy and
diagnostic methods are expressly excluded from patentability.77 The EPO states that
this is because they do not constitute an invention,78 but the EPO could have relied on
TRIPS to exclude them without narrowing the definition of invention. This exclusion
doesn’t apply to products or compositions of matter for use in such methods.79
Treatment of tissues after they have been removed and diagnostic mechanisms applied
to those tissues are patentable so long as the tissue isn’t returned to the same body.80
The EPO prohibits granting patents on inventions whose commercial exploitation
would be contrary to public morality.81 In particular, patents will not be granted on
the cloning of human beings, modification of the germ line of humans, the use of human
embryos for industrial or commercial purposes, or the modification of the genetic
identity of animals that are likely to cause them suffering without any substantial
medical benefit to man or animal.82
Plant and animal varieties and essentially biological processes for the production
of plants or animals are unpatentable under utility patents.83 Similar to methods of
surgery, the EPO defines plant and animal varieties as not inventions,84 but they are
allowed to explicitly exclude them from patentability even if they had met the
definition of invention. The EPO notes that plant patents are available in the national
offices of contracting states, but the EPO does not issue plant patents itself.85
Sexual crossing of whole genomes, even if other technical steps relating to
preparation or further treatment are present, are included in this prohibition against
patents on essential biological processes.86 This exclusion does not apply to microbial
processes or products.87 Biotechnology inventions are explicitly patentable if they

EUROPEAN PATENT OFFICE, EUROPEAN PATENT CONVENTION Art. 52, ¶29.
Id. ¶30.
78 Id.
79 Id.
80 Id.
81 Id. ¶31(a).
82 Id.
83 Id. ¶31.
84 Id.
85 Id.
86 Id.
87 Id.
76
77
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concern biological material that is isolated from its natural environment or produced
by means of a technical process even if its previously occurred in nature.88
C. Regulations of the Indian Office of Controller General of Patents, Designs, and
Trademarks
The Indian Manual of Patent Office Practice and Procedure Section 08.03.06 lists
fifteen categories of explicitly unpatentable inventions.89 These enumerated categories
are sometimes covered by more general doctrines of patentability in the Indian Manual
of Patent Office Practice and Procedure. An example of this double-coverage is that a
mere rearrangement of known components functioning independently, explicitly
banned under § 08.03.06.05, would fail the Indian Patent Office’s definition of
nonobviousness.90 Even so, the Indian patent office sees fit to list these novelty and
obviousness exceptions under their enumeration of specific exceptions to patentability,
and thus they will be listed here for the sake of completeness.
The Indian Office of the Controller General of Patents, Designs, and Trademarks
does not characterize most of the exceptions into the TRIPS categories, but there are
parallels with the categories of exceptions from countries that do characterize the
exceptions. India excludes plant varieties91 and the topography of integrated circuits,92
but provides intellectual property protection for these inventions in other sections of
its legal code.93 One listed exclusion that does not neatly fit into any of the allowable
TRIPS categories is India’s prohibition of patents on methods of agriculture.
1. Categories of Invention
Frivolous claims or inventions which claim anything obviously contrary to well
established laws such as perpetual motion machines are not patent eligible.94 Other
countries typically treat these incredible “inventions” which are not possible as not
qualifying for the status of an invention.
The discovery of a scientific principal or an abstract theory or a living thing or a
non-living substance occurring in nature is not patentable.95 A scientific principal used
in a process of manufacture does not make that process unpatentable.96 Given as an
example, the discovery that a material can withstand mechanical shock is an
unpatentable discovery; a railway sleeper made of the material is patentable.97
Id.
OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE, § 08.03.06 (India) (2010).
90 See Definition of “Inventive Step,” Manual of Patent Office Practice and Procedure § 02.02.04.
91 OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE, § 08.03.06.09.
92 Id. § 08.03.06.14.
93 Id. §§ 08.03.06.09, 08.03.06.14.
94 Id.
95 Id. § 08.03.06.03.
96 Id.
97 Id.
88
89
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Mathematical methods, business methods, computer programs, and algorithms
are ineligible for patents.98 Hardware with specific computer programs may be
patentable; however, a program which may work on any general-purpose computer is
not patentable.99
A scheme or rule or method of performing a mental act or a method of playing a
game are explicitly mentioned as unpatentable.100 Given examples of such methods
include a method of playing chess, a method of teaching, and a method of operating a
machine as per a set of instructions.101 These functions are considered as the outcome
of mere mental processes and thus not inventions.102
Literary, dramatic, musical, or artistic works are all excluded from
patentability.103 These works fall within the purview of the Indian Copyright Act of
1957.104 The Indian Office of the Controller General of Patents, Designs, and
Trademarks sees fit to explicitly exclude such works from the ambit of utility patents.
The presentation of information is unpatentable in India, no matter what form
this presentation takes.105 Given examples of unpatentable presentations of
information are railway tables, calendars, and rhythmic instructions for speeches.106
2. Novelty
A new form of a known substance that does not result in the enhancement of the
known efficacy or the discovery of a new property or new use of a known substance is
not patentable.107 The Indian Office of the Controller General of Patents, Designs, and
Trademarks notes that patents are not to be given on polymorphs, isomer mixtures, or
complexes of known material unless the new material differs significantly in properties
with regard to efficacy.108 This is in contrast to the United States, where “[i]somers
having the same empirical formula but different structures are not necessarily
considered equivalent by chemists skilled in the art and therefore are not necessarily
suggestive of each other.”109 The key here is the difference in burdens: Indian patent
applicants must prove different efficacy, whereas US patent applicants are given the
presumption of different efficacy. The Indian Office of the Controller General of
Patents, Designs, and Trademarks defines efficacy as the therapeutic effect, the
“healing a disease having a good effect on the body”110
Traditional knowledge or inventions that are an aggregation or duplication of
known properties of traditionally known components is unpatentable because it isn’t
Id. § 08.03.06.10.
Id.
100 Id. § 08.03.06.12.
101 Id.
102 Id.
103 Id. § 08.03.06.11.
104 Id.
105 Id. § 08.03.06.13.
106 Id.
107 Id. § 08.03.06.04.
108 Id.
109 MPEP § 2144.09.
110 OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE § 08.03.06.04.
98
99
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new knowledge.111 Specific examples include the antiseptic properties of turmeric for
wound healing and the pesticidal and insecticidal properties of neem.112
3. Nonobviousness
The Indian Office of the Controller General of Patents, Designs, and Trademarks
explicitly excludes from patentability mixtures of components where the resulting
properties are merely a mix of the properties of its component parts.113 Mixtures of
components that result in new properties, or mixtures that produce known properties
in a more economical manner are explicitly acknowledged as patentable.114
The mere arrangement, rearrangement, or duplication of known devices each
functioning independently is noted as unpatentable.115 Such a combination must be
more than a mere workshop improvement.116 The juxtaposition of devices which
function independently aren’t patentable.117 As mentioned earlier, this rearrangement
would fail the Indian Office of the Controller General of Patents, Designs, and
Trademarks’ definition of nonobviousness absent any explicit exclusion.118
4. TRIPS Article 27(2) & (3) Exclusions
Inventions whose primary or intended use or commercial exploitation would be
contrary to public order or morality, or which causes serious prejudice to human,
animal, or plant life or health, or to the environment, are excluded from patenting.119
Given examples of these inventions are a machine or method for committing burglary,
a method for counterfeiting currency, a method for gambling, methods of adulteration
of food, a method of cloning humans, and terminator gene technology.120
The Indian Office of the Controller General of Patents, Designs, and Trademarks
excludes from patentability any process used for the medicinal, surgical, curative,
prophylactic, diagnostic, therapeutic, or similar treatment of human beings, or the
parallel treatment of animals.121 Examples of excluded methods of treatment are
processes of administering medicines through a dermal patch, a method of stitch-free
surgical incision for cataract removal, a method of vaccination, and a method of
cleaning plaque from teeth.122 The application of substances to the body for purely
cosmetic purposes is not within the definition of therapy, and therefore patentable.123
Id. § 08.03.06.15.
Id.
113 Id. § 08.03.06.05.
114 Id.
115 Id. § 08.03.06.06.
116 Id.
117 Id.
118 See Definition of “Inventive Step,” MANUAL OF PATENT OFFICE PRACTICE AND PROCEDURE
§ 02.02.04.
119 MANUAL OF PATENT OFFICE PRACTICE AND PROCEDURE, § 08.03.06.02.
120 Id.
121 Id. § 08.03.06.08.
122 Id.
123 Id.
111
112
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Diagnostic methods are unpatentable, and they are defined as prohibited if they
include a deductive step of making the diagnosis and preceding steps constructive for
making that diagnosis involving specific interactions of a technical nature with the
human or animal body.124 Therefore, general fitness tests are patentable.125
For animals, any treatment to render them free of disease or to increase their
economic value is unpatentable.126 Given examples of exempt methods range from
methods for treating sheep for increasing wool yield, to methods of artificially inducing
the increase of the body mass of poultry.127
Plants and animals in whole or in part other than microorganisms are ineligible
for patent protection.128 Seeds or essential biological processes for production or
propagation of plants and animals are included in this prohibition. A method of
manufacture of a vaccine is patentable even though the end product contains a living
organism.129
5. Other Exclusions
Trademarks explicitly excludes methods of agriculture and horticulture from
patentability.130 Examples of such excluded methods include a method for producing a
new form of a known plant, a method of producing improved soil, a method of producing
mushrooms, or a method for cultivation of algae.131
The Indian Patent Office will not issue utility patents on the topography of
integrated circuits.132 These designs are otherwise protected under the Semiconductor
Integrated Circuit Lay-out Designs Act of 2000.133
D. Regulations of the Japan Patent Office
The Japanese Patent Examination Guidelines deals with excluding subject matter
in three distinct categories. Chapter 2.1 exempts certain subject matter from the
definition of invention, Chapter 3.1 exempts specified subject matter from being
considered industrially applicable, and Chapter 5.2 exempts specific subject matter
from being considered patentable due to concerns of public morality.

MANUAL OF PATENT OFFICE PRACTICE AND PROCEDURE, § 08.03.06.08.
Id.
126 Id.
127 Id.
128 Id. § 08.03.06.09.
129 Id.
130 Id. § 08.03.06.07.
131 Id.
132 Id. § 08.03.06.14.
133 Id.
124
125
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1. Categories Invention
The Japanese Patent Examination Guidelines note that a law of nature as such
is not a patentable invention.134 Given unpatentable inventions include the law of the
preservation of energy and the law of universal gravitation.135
Mere discoveries and not creations are not considered inventions by the Japan
Patent Office.136 Ores, natural phenomenon, and other discoveries where the applicant
“does not create any technical idea with intention” are ineligible for patent
protection.137 Chemical substances or microorganisms isolated artificially from their
surroundings are patentable.138
Claims for inventions that are contrary to a law of nature are ineligible for
patents.139 Perpetual motion machines and other incredible inventions are given as
examples of claims that are excluded from patentability under this section.140
Inventions where a law of nature is not utilized are unpatentable.141 This
exclusion includes economic laws, mathematical formula, mental activities, methods
for doing business, and arbitrary arrangements such as rules for playing a game.142
Computer programing languages are noted to usually be excluded from patentability,
but software for causing a computer to execute a method which is statutory is
patentable.143 Examples of computer programs that sufficiently execute a statutory
method are engine control software or software for running a polymerase chain
reaction machine.144
Subject matter that is not regarded as a technical idea is not patent eligible in
Japan.145 Inventions which are acquired through personal experience and skill that
cannot be shared with others as knowledge due to lack of objectivity, such as methods
of throwing a ball, are unpatentable.146 Mere presentations of information likewise
generally lack a sufficient technical idea.147 If technical features reside in the
presentation of information, it may be patentable, such as a test pattern for use in
checking the performance of a television set.148
Claims which purport to solve a problem, but it is clearly impossible to solve said
problem by any means presented in the claim, are unpatentable.149 A given example of
this exclusion is a method of preventing volcanic eruptions by throwing neutronabsorbing metal balls into a volcano would be unpatentable because volcanic eruptions

JAPAN PATENT OFFICE, PATENT EXAMINATION GUIDELINES, § 2.1.1 (Japan) (Oct. 1, 2015).
Id.
136 Id. § 2.1.2.
137 Id.
138 Id.
139 Id. § 2.1.3.
140 Id.
141 Id. § 2.1.4.
142 Id.
143 Id. § 2.2.
144 Id.
145 Id. § 2.1.5.
146 Id.
147 Id.
148 Id.
149 Id. § 2.1.6.
134
135
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are not caused by nuclear chain reactions, and thus neutron absorption would not serve
to prevent eruptions.150
2. Industrial Application
Inventions which are commercially inapplicable are unpatentable.151 In addition,
an invention only for personal use, such as a method for smoking, is unpatentable.152
Inventions which are for personal use but are still commercially applicable are
patentable, for example, a method for weaving hair is patentable due to its commercial
potential in the cosmetology market.153 Inventions which are only for academic or
experimental purposes are noted to be incapable of commercial application, and thus
excluded from patentability.154 Kits for scientific experiments are noted to have
commercial application, and thus do not fall into this category155
Obviously impracticable inventions are not eligible for patent protection because
they cannot be applied industrially.156 Even if the invention would work in theory, if
the application would be absurd, it is unpatentable. For example, a method for
preventing an increase of UV rays by covering the whole atmosphere with plastic film
could never be applied in practice, and so is excluded from patentability.157
3. TRIPS Article 27(2) & (3) Exclusions
The Japan Patent Office classifies inventions of methods of surgery, therapy, or
diagnosis of humans as unpatentable. This is due to their lack of industrial application,
and not under the exception provided for in TRIPS Article 27(3).158 However, animal
surgery or diagnosis is patentable if humans are explicitly excluded in the patent
claim.159 Methods excluded for patentability under this provision include methods of
implanting substitute organs, methods of preventing disease, and methods of
rehabilitative therapy.160 Medical devices are patentable, as are methods of extracting
samples and data from the human body and methods of analyzing those samples.161
Extracted samples are presumably not returned and so methods of diagnosis on them
is patentable.162 However, if a sample is to be returned to a human body, the claim may
still be patentable if it is a method for manufacturing a medical product, material, or
intermediate product made by utilizing raw material collected from a human body such
as vaccine preparation or a cultured sheet of skin.
JAPAN PATENT OFFICE, PATENT EXAMINATION GUIDELINES, § 2.1.6.
Id. § 3.2.2.
152 Id.
153 Id.
154 Id.
155 Id.
156 Id. § 3.1.3.
157 Id.
158 Id. § 3.2.1.
159 Id.
160 Id.
161 Id.
162 Id.
150
151
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Inventions which are liable to injure public order, morality, or public health are
unpatentable.163 The Japan Patent Office notes that it is very cautious when applying
this exception, noting that definitions of public morality can change with time.164 The
Office, in line with the TRIPS mandates, clearly states that an invention isn’t
unpatentable just because the exploitation of the invention is illegal under Japanese
law.165 Examples of categories of inventions that obviously injure public order and are
thus unpatentable are humans themselves produced through genetic manipulation, or
methods solely used to brutally massacre humans.166 Poisons, explosives, and
apparatuses used for punching holes in bank bills are all mentioned as patentable
since they do not meet the high bar of obvious injury to public order.167
E. Regulations of the Korean Intellectual Property Office
Similar to the Japanese patent system, the Korean Intellectual Property Office
Patent Examination Guidelines deal with excluding subject matter in three distinct
categories. Part III Chapter 4.1 exempts certain subject matter from the definition of
invention,168 Chapter 5.1 exempts specified subject matter from being considered
industrially applicable,169 and Chapter 6.1 exempts specific subject matter from being
considered patentable due to concerns of public morality.170
1. Categories of Invention
An invention is defined as “a highly advanced creation of a technical idea using
the rules of nature.”171 A law of nature as such is not patentable because it is, but does
not use a rule of nature.172 Therefore, no patent could be granted on the law of
conservation of energy.173
Mere discoveries and not creations are also not considered inventions, and thus
not patent eligible using the same logic.174 Things in nature that are isolated from their
surroundings and the methods of doing so are patentable, however.175

JAPAN PATENT OFFICE, PATENT EXAMINATION GUIDELINES, § 5.2.
Id.
165 Id.
166 Id.
167 Id.
168 KOREAN INTELLECTUAL PROPERTY OFFICE, PATENT EXAMINATION GUIDELINES, 199 (S. Kor.)
(July 2013).
169 Id. at 205.
170 Id. at 308.
171 Id.
172 Id.
173 Id.
174 Id. § 4.1.2.
175 Id.
163
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Claims to inventions that are contrary to the laws of nature are unpatentable, as
such claims cannot use a law of nature.176 Perpetual motion machines are within this
exception to patentability.177
Claims where a law of nature is not utilized at all are not considered inventions,
and neither are arbitrary arrangements nor mental processes.178 Economic laws,
mathematical methods, and business methods all fail to utilize a law of nature, and
are thus unpatentable.179 The claim as a whole must utilize a law of nature – individual
steps may not invoke a law of nature, but the claim may still be patentable if other
parts of the invention sufficiently use laws of nature.180
A personal skill “acquired by personal practice cannot be shared with third parties
as knowledge due to lack of objectivity, so it is not considered to be a statutory
invention.”181 A method for throwing a ball or a method of performing musical
instruments are given as examples of unpatentable skills.
The mere presentation of information is unpatentable, and the presence of a
technical feature does not render it patentable if the main objective of the technical
feature is to present the information.182 Information on a CD is therefore unpatentable,
but the novel feature of raised numbers on a credit card presents a sufficient technical
feature to be patentable, even though the end result is the conveyance of
information.183 Likewise, aesthetic creations on their own are not patentable.184
However, a subjective evaluation must be made as to the technical nature of any
aesthetic creation; if the creation is “achieved by technical composition or other
technical means,” it is patentable.185
Computer programming language or computer programs are not patentable.186
Computer programs are viewed as simply a list of orders and thus don’t constitute an
invention.187 However, where a computer program is specifically executed using
hardware, the machine in association with the program may be patentable.188
If the outcome of an invention is not achievable or reproducible, the Korean
Intellectual Property office notes that the claim is not eligible for patent protection.189
This does not mean the invention must be one hundred percent reproducible, but it
should not be impossible or random in its outcome.190

KOREAN INTELLECTUAL PROPERTY OFFICE, PATENT EXAMINATION GUIDELINES, § 4.1.3.
Id.
178 Id. § 4.1.4.
179 Id.
180 Id.
181 Id. § 4.1.5.
182 Id. § 4.1.6.
183 Id.
184 Id. § 4.1.7.
185 Id.
186 Id. § 4.1.8.
187 Id.
188 Id.
189 Id. § 4.1.9.
190 Id.
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Incomplete inventions are not eligible for patent protection.191 If the claim lacks a
concrete means to solve the problem posed, there is not an invention within the
claims.192
2. Novelty
The Korean Intellectual Property Office notes only one explicit exception to
patentability under the aegis of novelty: a new use of a known material is patentable
as a method, but the material itself is not patentable.193
3. Industrial Application
Similar to the Japan Patent Office, inventions that cannot be commercialized are
explicitly excluded from patentability.194 Inventions that are only for personal use,
academic, or experimental purposes are thus unpatentable.195 However, if the
invention covers marketable or tradable subject matter, it overcomes this bar.196
Inventions that cannot be implemented are excluded from patentability by failing
the test for industrial applicability.197 The Korean Intellectual Property Office uses the
same example as the Japan Patent Office for illustrating this exception: an invention
for preventing an increase in UV rays by covering the earth’s surface with plastic film
lacks industrial applicability, and is thus excluded from patentability.198
4. TRIPS Article 27(2) & (3) Exclusions
Like the Japan Patent Office, the Korean Intellectual Property Office will not
grant patents on the practice of medicine because it does not have industrial
application, not because of the TRIPS exception.199 A method for treatment of the
human body by surgery or therapy is unpatentable.200 Treatments with mixed
therapeutic and nontherapeutic or cosmetic effects are considered therapeutic, and
thus unpatentable.201 In contrast, medical devices and diagnostic methods practiced
on samples removed from the human body are patentable.202
Inventions that are likely to contravene public order or morality are
unpatentable.203 The primary use of an invention must be to contravene public order
KOREAN INTELLECTUAL PROPERTY OFFICE, PATENT EXAMINATION GUIDELINES, § 4.1.10.
Id.
193 Id. § 4.1.2.
194 Id. § 5.2.
195 Id.
196 Id.
197 Id. § 5.3.
198 Id.
199 Id. § 5.1.
200 Id.
201 Id. § 5.1.
202 Id.
203 Id. § 6.3.1.
191
192
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to be excluded from patentability; incidental immoral use, or use in a way other than
the invention’s original purpose, is not enough to exclude the invention from
patentability.204 Bingo, although used for gambling, is primarily used for
entertainment, and is given as an example of an invention that, if claimed properly, is
patentable.205
Inventions likely to injure public health are excluded from patentability.206 Like
the public morality analysis, the primary use of an invention must be to injure public
health for the patent office to invoke this exception.207 Examiners are directed to weigh
the claimed useful benefit against the harm to public health when, in the invention
accomplishing its original useful purpose, it produces a result that is harmful to public
health.208
F. Regulations of the Singaporean Patent Office
Singapore’s Examination Guidelines for Patent Applications at the Intellectual
Property Office of Singapore Chapter 8 details exclusions from patentability.209 The
Singaporean Patent Office has extensive guidance on how the exclusion of medical
patents should be applied, and provides a good case study for the intricacies that arise
in administering the prohibition on medical treatment patents.
1. Categories of Invention
The Singapore Examination Guidelines state that examiners should look at
claims to determine if they are an “invention” by “identify[ing] the actual contribution
which is made by the claimed subject matter, having regard to the problem to be solved,
how the claimed subject matter works, and what its advantages are.”210
The presentation of information is not considered an invention and is therefore
unpatentable.211 Functional presentations may be patentable, such as the presentation
of information in a newspaper that did not obstruct folding.212 The source code for
software isn’t patentable, as it is merely information and not a functional
presentation.213
Discoveries are not inventions under Singaporean patent law.214 An invention
requires that a “patentee must do something more; he must make some addition, not
only to knowledge, but to previously known inventions, and must so use his knowledge
KOREAN INTELLECTUAL PROPERTY OFFICE, PATENT EXAMINATION GUIDELINES, § 6.3.1.
Id.
206 Id. § 6.3.2.
207 Id.
208 Id.
209 EXAMINATION GUIDELINES FOR PATENT APPLICATIONS, INTELLECTUAL PROPERTY OFFICE OF
SINGAPORE, 259 (Sing.) (2017).
210 Id. § 8.3.
211 Id. § 8.27.
212 Id.
213 Id.
214 Id. § 8.9.
204
205
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and ingenuity as to produce either a new and useful thing or result, or a new and useful
method of producing an old thing or result.”215 The discovery of a new property of a
material is specifically mentioned as unpatentable, but if the property results in a new
use, that use may be patentable because the new use is “something more,” and thus
properly an invention.216
Natural products are considered discoveries and thus not eligible for patent
protection.217 Materials and microorganisms found in nature aren’t patentable, even if
isolated and purified.218 Uses of the purified materials may be patentable, though.219
In addition, modifications from the natural form in order to make the natural product
more suitable to some use may make the material or organism patentable.220 Claims
directed towards processes that exist in nature are not allowed, but a claim to a specific
use of such a process is allowed.221 For example, the process of producing a beverage
by digesting milk using natural proteases is patentable, even if the claim to the process
of digesting milk using natural proteases isn’t.222
DNA is explicitly noted as an exception to patentability, as its value is only in the
information encoded, and deviation from the natural product may represent no more
than a chemical curiosity.223 The resulting protein is also not patentable, as it is a
product of nature. However, the process of making the protein is patentable.224
Scientific theories and mathematical models are noted to not be inventions.225 The
use of such a theory, if done in a novel, nonobvious, and industrially applicable way, is
explicitly patentable, however;226 reciting the theory and stating “apply it” does not
constitute the use of the theory.227 Therefore, the theory of relativity is not patentable,
but the global positioning system which relies on the theory of relativity is
patentable.228
Aesthetic creations, literary, dramatic, musical, and artistic works are noted to
not be inventions, whether they be the mental processes to produce such works or the
physical embodiments of the works.229 Designs which import some function may be
patentable, such as improved non-slip patterning.230
Schemes, rules, or methods for performing a mental act, playing a game, or doing
business are explicitly not considered inventions.231 These excluded categories include

215 EXAMINATION GUIDELINES FOR PATENT APPLICATIONS, INTELLECTUAL PROPERTY OFFICE OF
SINGAPORE, § 8.9.
216 Id. § 8.10.
217 Id. § 8.14.
218 Id. § 8.12.
219 Id.
220 Id. § 8.14.
221 Id. § 8.15.
222 Id.
223 Id. § 8.15.
224 Id.
225 Id. § 8.17.
226 Id. § 8.19.
227 Id. § 8.21.
228 Id. § 8.18.
229 Id. § 8.22.
230 Id. § 8.23.
231 Id. § 8.25.
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teaching methods and methods for design, but a method for design plus a
manufacturing step may be patentable.232
2. Nonobviousness
The mere combination of isolated and purified natural products with known
materials does not grant patentability unless the combination goes beyond just putting
the combination together, and results in a specific useful application.233
3. Industrial Application
A claim to subject matter that is contrary to established physical laws is
unpatentable.234 Perpetual motion machines have no industrial applicability, and so
are excluded from patentability.235
4. TRIPS Article 27(2) & (3) Exclusions
Singapore has a very detailed explanation of exceptions under the patentability
exclusion for medical use. Methods of medical treatment practiced on the human or
animal body are excluded from patentability under the rationale that they are not
industrially applicable.236 All methods of therapy are excluded from patentability,
including preventative treatment, vaccines, any methods to alleviate disease
symptoms, any curative treatment, and any veterinary treatment of a diseased or
injured animal, including prophylactic and immunotherapeutic treatment.237 If it is
possible to establish a direct link between the method and the disease being cured,
prevented, or alleviated under either western medical standards or traditional Chinese
medicine, the method is expressly excluded from patentability.238 Methods that result
in the death of the subject, such as the given example of a method for the sacrifice of
laboratory animals, are patentable because they are not therapeutic.239 Dual-use
technologies can be patented so long as the claim doesn’t encompass therapeutic use.240
Thus, The Intellectual Property Office of Singapore gives the example of a method of
using a certain molecule to prevent the coagulation of blood would not be allowed due
to the therapeutic uses of the molecule, but if the claim was restricted to the use of the
molecule to prevent the coagulation of blood for storage or collection in a blood bank,
232 EXAMINATION GUIDELINES FOR PATENT APPLICATIONS, INTELLECTUAL PROPERTY OFFICE OF
SINGAPORE, § 8.26.
233 Id. § 8.14.
234 Id. § 8.31.
235 Id.
236 Id. § 8.33.
237 Id. § 8.37.
238 Id. § 8.38.
239 Id. § 8.49.
240 Id. § 8.44.
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the claim would be allowed.241 Methods of abortion are noted as explicitly unpatentable
under the aegis of medical treatment, not on public policy grounds, even though
methods of abortion do not fall within the definition of therapy used for the rest of the
section.242
Singapore has special statutory provisions for first and second medical use of
compositions of matter to allow patents for methods using known compounds for
therapeutic purposes.243 These provisions allow for both composition and method
patents for pharmaceuticals when the method patents would be otherwise barred by
the blanket ban on patents on therapies.
Methods of surgery on humans or animals are explicitly not patentable.244 To
qualify as a method of surgery, the claim must cover the kind of interventions which
represent the core of the medical profession’s activities.245 Method for cosmetic ear
piercing or a method of tattooing are patentable because they do not require the
application of medical skill or knowledge.246 The treatment of samples after they have
been removed from the body and won’t be returned to the same body is patentable;247
dialysis is not patentable because the blood is returned to the same body.248
Methods to increase the economic value of livestock through increased meat, eggs,
milk, or other improvements may be patentable.249 However, these claims must be
limited to non-therapeutic uses to be patentable.250 If the increased meat yield comes
either as a direct result of increased health because of the therapeutic use of the
method, or there is an incidental therapeutic use, the claim is unpatentable.251
Diagnostic methods practiced on the human or animal body are unpatentable.252
The Intellectual Property Office of Singapore defines diagnosis as four steps leading
toward the identification of a condition:
1. The examination and collection of data;
2. Comparison of the data with normal values;
3. Recording any deviation from the norm; and finally,
4. Attributing the deviation to a particular clinical picture.253

241 EXAMINATION GUIDELINES FOR PATENT APPLICATIONS, INTELLECTUAL PROPERTY OFFICE OF
SINGAPORE, § 8.84
242 Id.
243 Id. § 8.111.
244 Id. § 8.33.
245 Id. § 8.52.
246 Id. § 8.53.
247 Id. § 8.91.
248 Id. § 8.90.
249 Id. § 8.72.
250 Id.
251 Id. §§ 8.73, 8.74.
252 Id. § 8.92.
253 Id. § 8.93.
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Any method that accomplishes these steps is unpatentable.254 However, the
Intellectual Property Office of Singapore notes that if a diagnostic method is carried
out on a dead human or dead animal body, it is patentable.255 Fitness tests and other
methods for determining general health, but not a specific pathological condition, are
patentable.256
Singapore bans the patenting of morally objectionable claims.257 Claims may be
rejected as morally objectionable if they encompass one of the prohibited activities of
the Human Cloning and Other Prohibited Practices Act (“HCOPPA”),258 or the Human
Biological Research Act (“HBRA”).259 These laws prohibit on ethical grounds the
cloning of humans or the development of a human embryo outside of a woman for more
than fourteen days, among other acts relating to the treatment of human embryos.260
Claims to methods of producing human stem cell lines are generally allowable,261 as
are claims to genetically modified organisms or transgenic organisms.262
G. Regulations of the United States Patent and Trademark Office
United States patent law subject matter eligibility is codified in 35 U.S.C. § 101,
and gives inventors of “any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof, [the right to] obtain
a patent therefor, subject to the conditions and requirements of this title.”263 Compared
to the other patent regulations analyzed so far, the United States has very few explicit
exceptions to patentability.
1. Categories of Invention
The United States Patent and Trademark Office (“USPTO”) Manual of Patent
Examining Procedure Section 2104 outlines how the USPTO deals with the question
of what constitutes an invention.264 The USPTO uses a two-step procedure: first, is the
claim directed towards one of the categories of statutory exceptions; second is the claim
directed towards one of judicially recognized exceptions to patentability.265
The four statutory categories are process, machine, manufacture, and composition
of matter.266 A process is an act or series of steps.267 A machine is “a concrete thing,

EXAMINATION GUIDELINES FOR PATENT APPLICATIONS (Sing.) § 8.94.
Id. § 8.95.
256 Id. § 8.108.
257 Id. § 8.185.
258 Id. § 8.194.
259 Id. § 8.200.
260 Id. § 8.198.
261 Id. § 8.199.
262 Id. § 8.203.
263 35 U.S.C. §101 (2012).
264 MPEP § 2104.
265 Id.
266 MPEP § 2106; 35 U.S.C. § 101.
267 MPEP § 2016; Gottschalk v. Benson, 409 U.S. 63, 72 (1972).
254
255
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consisting of parts, or of certain devices and combination of devices.268” A manufacture
is “an article produced from raw or prepared materials by giving to these materials
new forms, qualities, properties, or combinations, whether by hand labor or by
machinery.”269 Finally, a composition of matter is “all compositions of two or more
substances and all composite articles, whether they be the results of chemical union,
or of mechanical mixture, or whether they be gases, fluids, powders or solids, for
example.”270 Examples of subject matter that, without more, is outside these four
defined categories are propagating electromagnetic signals, a legal contractual
agreement, a computer program, and an arrangement of printed matter.271
If the claim fits into one of the statutory categories, a patent may not be issued if
the subject matter wholly embraces a judicial exception without adding significantly
more.272 The judicial exceptions include laws of nature, natural phenomenon, abstract
ideas, scientific principles, mental processes, and disembodied mathematical
algorithms and formulas.273 The judiciary has theorized that such “‘manifestations of
laws of nature’ are ‘part of the storehouse of knowledge,’ ‘free to all men and reserved
exclusively to none.’”274 Therefore, both a mineral found in the earth and E=mc2 are
not inventions under United States patent law. Until recently, the USPTO recognized
isolated and purified natural products as inventions, but this has been overturned by
Association for Molecular Pathology v. Myriad Genetics,275 which held that DNA
isolated and purified is unpatentable as a product of nature.276 The USPTO has
extended this reasoning to hold all natural products are unpatentable even if isolated
and purified without a showing of markedly different properties from the natural
form.277
2. Industrial Application
The United States uses the term “useful” to describe the necessity of industrial
application for inventions, and explains the requirements for utility in Section 2107.278
The USPTO requires that a claim have specific and substantial utility to be
patentable.279 Specific utility means a present definite use for the invention and
substantial utility means it has a real world use.280 Examples of inventions which fail
this test are methods for treating an unspecified disease, or an intermediate molecule
MPEP § 2106; Burr v. Duryee, 68 U.S. (1 Wall.) 531, 570 (1864).
MPEP § 2106; Diamond v. Chakrabarty, 447 U.S. 303 (1980).
270 MPEP § 2106; Chakrabarty, 447 U.S. at 308.
271 MPEP § 2106 (2018).
272 MPEP § 2106; Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208, 216 (2014).
273 MPEP § 2106; Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208, 218 (2014).
274 MPEP § 2106; Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
275 MPEP § 2106.
276 Id.
277 Memorandum from Robert W. Bahr, Deputy Commissioner, United States Patent and
Trademark Office, to Patent Examining Corps on Formulating a Subject Matter Eligibility Rejection
and Evaluating the Applicant's Response to a Subject Matter Eligibility Rejection (May 4, 2016) (on
file with the USPTO).
278 MPEP § 2107.
279 Id.
280 Id.
268
269
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in a chemical synthesis with no use except to get to the end product.281 Inventions
asserting utility for the treatment of human or animal disorders must identify some
specific usefulness by identifying any pharmacological activity to pass this bar.282
The USPTO will not issue a patent for wholly inoperative inventions, inventions
that claim incredible utility, or to inventions which contravene laws of nature.283
Therefore, no patents will be issued to perpetual motion machines.284
3. TRIPS Article 27(2) & (3) Exclusions
The Leahy-Smith America Invents Act (“AIA”) changed United States patent law
to exempt human organisms from patentability.285 The USPTO had until the AIA issue
patents on human genes,286 human stem cells, and transgenic animals, but had not
issued patents on claims directed towards human embryos, fetuses, or human
organisms.287 This change in law codified the existing practice and the USPTO
continues to issue patents on stem cells and transgenic animals.
III. COMMONALITIES AND DIFFERENCES IN NATIONAL PATENTABILITY EXCEPTIONS
A. Categories of Invention
Patent offices the world over have come to a somewhat unified understanding of
what exclusions there should be in order to define categories of invention. Generally,
discoveries, scientific principles, and mathematical equations are explicitly excluded
from patentability. These exclusions reflect the idea that the patent monopoly should
not be used to preclude the use of the foundational building blocks of innovation. If a
scientist discovers a new principal of physics, they must bring some concrete benefit to
society in the form of a tangible invention using the new principal in order to be
rewarded for their discovery. Likewise, purely mental processes are excluded from
patentability by most patent offices because they are the “basic tools of scientific and
technological work.”288
The fine arts are excluded from the definition of an invention, either explicitly or
implicitly, save for Canada, where they are seen as industrially inapplicable.289
MPEP § 2107.01.
MPEP § 2107.03.
283 MPEP § 2107.01.
284 Id.
285 MPEP § 2105; Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat.
284, 340 (2011).
286 But see Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 590-591 (2013).
287 MPEP § 2105; 157 CONG. REC. E1177-04, E1180 (daily ed. June 23, 2011) (testimony of
Representative Dave Weldon previously presented in connection with the Consolidated
Appropriations Act, 2004, Public Law 108-199, 634, 118 Stat. 3, 101, (later resubmitted with regard
to the AIA); see 149 Cong. Rec. E2417-01).
288 Gottschalk v. Benson, 409 U.S. 63, 67 (1972).
289 CANADIAN INTELLECTUAL PROPERTY OFFICE, MANUAL OF PATENT OFFICE PRACTICE §12.03.07
(Can.) (2017).
281
282
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Inventing, although creative work, is thought to require different incentives than the
pure creative exercise of artists.290 The goal of a patent system is to encourage repeated
innovation, which requires building on the ideas and implementations of previous
inventions.291 This iterative process requires different incentives to function correctly
than the fine arts, which are given protection suited to the needs of fostering the arts
under the auspices of copyright law.292
Computer systems untethered to specific machines or processes are generally
considered to be a mere list of orders or instructions untethered from an inventive
activity and so not offered patent protection.293 As TRIPS notes, computer programs
can be covered by copyright,294 in recognition of the creative nature of writing the
program. Because artful claim drafting can fit a claim for a computer program into the
requirements for a process claim, most countries have explicitly excluded computer
programs from patentability.
Frivolous or incredible inventions are the final, generally-accepted exclusions
from patentability. Perpetual motion machines or claims to compounds that cure death
are so outside the bounds of what is considered scientifically plausible that they do not
fulfill the patent bargain of disclosing new innovations. Additionally, patent offices
don’t want to spend the resources dealing with a deluge of spurious inventions and so
have a blanked prohibition against this kind of subject matter.295 Some countries deal
with these incredible inventions by ruling that they lack industrial applicability
instead of saying that they are not inventions, but the end result is the same.
In contrast to these agreed-upon norms, countries have come do different
conclusions to the question of if a skill is patentable. South Korea and Japan both
explicitly exclude skill acquired through personal experience.296 They hold that
personal skill lacks a sufficient technical idea to render it an “invention.” These
countries feel that describing a better method of throwing a ball is of insufficient
importance to give a patent monopoly. Other countries do not attach a specific
minimum technical requirement to qualify for inventions, and so methods relating to
personal skill are inventions.297
B. Novelty
Countries have very few listed specific exceptions to the requirements of novelty.
India and South Korea list specific exceptions that are covered in more general terms
in other country’s patent laws.298 The requirements of novelty dictate the claim not
290 What is Intellectual Property, WIPO, http://www.wipo.int/edocs/pubdocs/en/intproperty/450/w
ipo_pub_450.pdf (last visited Mar. 27, 2019).
291 Suzanne Scotchmer & Jerry Green, Novelty and Disclosure in Patent Law, 21 RAND J. ECON.
131, 133 (1990).
292 Id.
293 See supra Part II.E.1.
294 TRIPS Art. 10.
295 Gene Quinn, The Patent Law of Perpetual Motion, IPWATCHDOG, http://www.ipwatchdog.co
m/2011/10/11/the-patent-law-of-perpetual-motion/id=19828/ (last visited Mar. 27, 2019).
296 See supra Part II.D.2, Part II.E.1.
297 U.S. Patent No. 5,280,906 (issued Jan. 25, 1992).
298 See supra Part II.C.2.
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cover things already available to the public. Therefore, as the exceptions that Japan
and South Korea list point out, a new use of a known material is patentable, even if
the material itself is not patentable again.
The EPO, 299 Japan, 300 and South Korea301 all allow patents on isolated and
purified natural products, even if the chemical structure of the product is identical to
that which exists in nature. Until recently the United States also recognized this
isolated and purified exception to the novelty rule on the basis that even if the chemical
structure is not novel, the isolated and purified form of it was a novel state and thus
worthy of patent protection.302 Furthermore, it was worth the cost to society of a patent
grant to incentivize research into compounds from the natural world, and so this lessstrict application of the novelty requirement was acceptable. Due to the Supreme
Court’s recent ruling in Association for Molecular Pathology v. Myriad,303 the United
States has joined Singapore in excluding isolated and purified natural products from
patentability.
India is the only country to specifically exclude traditional knowledge from
patentability due to it not being novel. Traditional knowledge may be excluded from
patenting under novelty considerations if the claim is entirely known, but India
specifies this as a listed exemption to patentability. The implications of traditional
knowledge on patentability have been a topic at WIPO, and WIPO has cautioned
against granting patents that are not novel or nonobvious in light of traditional
knowledge.304
C. Nonobviousness
Similar to novelty, countries have very few listed specific exceptions to the
requirements of nonobviousness, and those that are listed are generally covered by
other countries’ more general nonobviousness rules. For example, India specifically
exempts combinations of components or independent machines where the resulting
properties do not produce results that are different than an admixture of the
components. This is the same result that would be obtained by applying the rules of
nonobviousness to the situation in other countries absent a specific exclusion.305
Singapore includes an exclusion for a mixture containing isolated and purified natural
products that similarly fits within the purview of obviousness analysis in other
countries. Isolated and purified natural products are not patentable in Singapore, and
the Singaporean patent regulations exclude a mixture of natural product with non-

See supra Part II.B.2.
See supra Part II.D.1.
301 See supra Part II.E.1
302 See Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911).
303 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 596 (2013).
304 Recognition of Traditional Knowledge within the Patent System, Intergovernmental Committee
on
Intellectual
Property
and
Genetic
Resources,
Traditional
Knowledge,
and
Folklore, WIPO (Sept. 18, 2008), https://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_13/wipo_grtk
f_ic_13_7.pdf.
305 See MPEP § 2144.06.
299
300
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natural materials from patentability unless the admixture produces some result
besides that which would be expected from the combination of the components.306
D. Industrial Application
In the patent bargain, there must be some exchange for the patent monopoly,
some benefit that the invention can bring to the public. This fundamental requirement
is seen in the limited exceptions the studied nations give to the requirement of
usefulness or industrial applicability. However, the theories that countries use to
obtain this balance are vastly different in background. These different backgrounds
mean that if the standard of industrial applicability is applied with rigor, there could
be vastly different outcomes for the same invention. In practice, countries maintain
the industrial applicability standard as a very low bar,307 so only edge cases provide
different outcomes for patentability analysis. However, there is one edge case that
bears examination: must the invention be commercializable?
Canada rejects inventions that do not solve a practical problem as industrially
inapplicable. This is in contrast to Japan and South Korea, who reject inventions that
are commercially inapplicable, and the United States, which rejects inventions that do
not have specific and substantial utility. How these different philosophies manifest is
evident in the exceptions to patentability each country lists.
As Canada is looking for the solution to a practical problem, inventions which are
merely incidental to solving a problem, such as a novel aesthetic feature on a machine
that does not impact the functioning of the machine, are listed as specific exclusions to
patentability. This approach blends the analysis of categories of invention and
industrial applicability together by holding these disembodied improvements to
something other than solving a problem are inventions, just not patentable inventions.
The typical definition of invention involves solving a problem, and so this blended
approach to industrial applicability can be viewed as more of a restatement of the
categories of inventions.
Canada’s blended invention-industrial applicability approach is similar to the
United States’ approach, where the invention must have specific and substantial
utility. Like Canada, a patentable invention in the United States must identify
something that the invention is doing, some problem it is solving. This requires that
the applicant identify some present real-world problem (satisfying substantial utility)
and make a claim that the invention is remedying it (satisfying specific utility).
Therefore, as the United States Manual of Patent Examining Procedure points out, a
patent can’t be granted on a molecule to be used as a drug without identifying what
condition the molecule is supposed to ameliorate. These standards, although worded
differently and illustrated with different exclusions, are merely an extension of the
question of what is an “invention,” and, as such, both countries come to similar
conclusions on patentability.
306 INTELLECTUAL PROPERTY OFFICE OF SINGAPORE, EXAMINATION GUIDELINES FOR PATENT
APPLICATIONS, § 8.31 (Sing.) (2017).
307 See, e.g., Julie Desrosiers & Michael Shortt, Supreme Court Rejects the “Promise of the
Patent” Redefines Canada’s Patent Utility Requirement, FASKEN, https://www.fasken.com/en/knowle
dgehub/2017/07/intellectualpropertybulletin-20170704 (last visited Mar. 27, 2019).
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India lists no specific examples of inventions that are unpatentable due to
industrial applicability, but does require that the invention “is capable of being made
or used in an industry.”308 The Indian Patent Office takes a stance on industrial
applicability similar to the United States: a general statement that the compound “may
be useful in treating unspecified disorders, or that the compound has ‘useful biological’
properties”309 is insufficient industrial applicability, but if some use is identified, the
patent office will not reject the claim on these grounds. Singapore takes a nearly
identical tact to India but lists the specific example of perpetual motion machines as
lacking industrial applicability.
In contrast to Canada, the United States, India, and Singapore, Japan and South
Korea require inventions to be commercializable. This is expressed in the listed
exceptions: inventions which are only for personal use, academic use, or experimental
purposes are unpatentable. This definition extends industrial applicability beyond a
refinement of defining an invention but mandates that an invention must be useful in
commerce. Therefore, inventions which pass the utility bar in the United States may
not fulfill the requirements for industrial applicability in Japan and South Korea.310
An invention that may fall foul of this industrial application requirement would be a
transgenic mouse useful for research into neurotransmitter properties in humans.311
The applicant must argue that there is some industrial application to this mouse
outside of the research context, a bar that would be hard to surmount.
An interesting view into the interplay of the standard for invention and
patentability is seen in how Canada and Japan handle cosmetology. Canada says
explicitly that methods of cosmetology are not inventions, and thus not patentable
because they are a fine art. Canada therefore does not reach the question of if advances
in cosmetology are the solution to practical problems. Japan, on the other hand, does
not have an express prohibition on inventions in the fine arts, and expressly allows
patents on cosmetology methods such as a method of weaving hair due to its
applicability in the beauty industry, which Japan sees as sufficient commercial
application.
In interpreting the requirement for industrial applicability, two camps have
developed. One, composed of Canada, the United States, India, and Singapore, has a
very low standard of industrial applicability, using this criterion as a second check on
categories of invention. Japan and South Korea treat industrial applicability as an
actual requirement, mandating a showing of comercializability that far exceeds
anything other countries ask for. Japan and South Korea thus don’t provide public
incentives for research into technologies that do not bring profit but may bring other
benefits to society, such as research tools; on the other hand if these technologies are
developed, Japan and South Korea allow for more widespread dissemination due to the
lack of patent protection. However, if it turns out there is later discovered a commercial
use, the initial inventor cannot capture the benefit of that development. This approach
is in contrast to the United States’ approach, which allows patents on research tools
308 THE OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS, AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE, § 08.03.04 (India) (2010).
309 MPEP § 2107.01.
310 Jay Erstling, Korea’s Patent Policy and Its Impact on Economic Development: A Model for
Emerging Countries?, 11 SAN DIEGO INT. L.J. 441, 450 (2010).
311 See, e.g., U.S. Patent No. 5,932,780 (issued Aug. 3, 1999).
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but has a relatively liberal experimental use exception to patent infringement.312 This
allows the inventor to capture the benefit of their invention commercial activity, even
if it is unknown at the time of application, without precluding basic research. In the
United States, the inventor of a currently commercially useless invention must make
the decision of if the patent office fees are worth the chance to capture future
commercial uses; in Japan and South Korea the inventor has this choice made for
them, and is thus incentivized to maintain the invention as a trade secret until a
commercial use is found. This model of granting patents on commercially inapplicable
inventions, coupled with a liberal experimental use exception, would give inventors
the agency to decide if the benefits of farsighted research outweigh the costs, and thus
spur speculative innovation more broadly into technology that is currently
commercially inapplicable and promote earlier disclosure to the public, compared to a
system where the inventor must find a commercial application themselves before a
patent could be granted.
E. TRIPS Article 27(2) & (3) Exclusions
1. Public Morality
Most countries studied in this Article have some patentability exception for public
morality, but the scope of the exception differs significantly. Canada lacks any sort of
exception for inventions which offend public morality. Some of the most likely
inventions to offend, such as patents on transgenic humans, human embryos, or
human fetuses, are covered by Canada’s prohibition on patenting higher life forms.
Patents on embryonic stem cell lines, and methods of producing them, are mentioned
as statutory subject matter, and are patentable in Canada. The United States does not
have a statutory prohibition against patenting higher life forms, but does have an
explicit prohibition on issuing patents for human embryos, fetuses, or organisms.
There is no prohibition on patenting human stem cells. Likewise, Singapore bans the
patenting of humans and human cloning, but does so by prohibiting on ethical grounds
any conduct that is prohibited by two other national laws about human biological
research. Therefore, with regard to patents on humans in any stage of development,
Canada, the United States, and Singapore achieve generally the same result by
different means.
The Japanese Patent Office has a broader prohibition on patents for amoral
inventions, but cautions that it is to be applied sparingly, and not just because the
invention is illegal to use under Japanese law. In addition to the prohibitions on
humans that Canada and the United States enforce, Japan also will not issue a patent
on methods whose only purpose is to harm, such as a method to brutally massacre
humans. The EPO has similar statutory language as Japan, but takes a broader stance
on the prohibition of issuing patent on public morality grounds. EPO regulations
prohibit patenting inventions whose commercial exploitation would be harmful to
312 Ted Hagelin, The Experimental Use Exceptions to Patent Infringement, NYSTAR RESEARCH
REPORT (Sept. 2008), http://nysstlc.syr.edu/wp-content/uploads/2014/09/NYSTAR-The-ExperimentalUse-Exemptions-to-Patent-Infringement-Fall-2005.pdf.
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public morality, such as methods of cloning human beings or the use of human embryos
for commercial purposes.
The South Korean Patent Office excludes more inventions from patentability than
the EPO. Incidental amoral use isn’t a bar, but South Korea would ban an invention if
the invention’s intended use was gambling. Given the examples the EPO provided for
unpatentable amoral inventions, South Korea’s ban on inventions for gambling is
likely a lower bar than the EPO would invoke.
India has the most expansive nationalization of TRIPS Article 27(2), incorporating
it verbatim into its national regulations. It also lists the most expansive roster of
examples of prohibited inventions, from burglary tools to terminator gene technology.
The inclusion of terminator gene technology, a method by which farmers are required
to re-buy genetically modified seeds from the manufacturer instead of replanting them,
is unique to India. There is significant debate about the ethics of terminator gene
technology, especially when applied to food crops,313 but the prohibition on granting a
patent does not otherwise outlaw the technology, which in the end may make it more
widespread in India. Interestingly, given India’s broad prohibitions, there are no
concrete examples of innovations that are unpatentable due to their harm the
environment.
2. Diagnostic, Therapeutic, or Surgical Methods
All countries studied exclude from patentability, either de facto or de jure, patents
on medical treatment of humans, although the scope of this prohibition varies. The
United States has the most permissive regime, having no exceptions to the granting of
patents on diagnostic, therapeutic, or surgical methods. However, 35 USC 287(c)
immunizes health care professionals and related institutions from infringement of
patents for medical or surgical (but not diagnostic) activities.314 Therefore, patents on
medical techniques on humans do not grant a monopoly because they give no ability to
restrain infringement by the only users of the methods on humans. Thus, although the
United States does not have a ban on granting patents on medical methods for humans,
it has a de facto ban because of their uselessness as a monopoly for the inventor.
Canada excludes methods of therapy or surgery on living humans from
patentability, but does not ban patents on methods of diagnosis. This is in contrast to
the EPO, Japan, South Korea, India, and Singapore, who ban patents on diagnostic,
therapeutic, and surgical methods. The EPO bases these exclusions on the notion that
medical methods are not inventions, while Japan, South Korea, and Singapore state
that such methods are not industrially applicable, and thus unpatentable. The end
result of this logic though is virtually identical: methods to “cure, prevent or ameliorate
an ailment or pathological condition, or treat a physical abnormality or deformity”315
313 What’s the Controversy over GMOs and “Terminator” Seeds?, GENETIC LITERACY PROJECT,
https://gmo.geneticliteracyproject.org/FAQ/whats-controversy-gmos-terminator-seeds/ (last visited
Mar. 27, 2019).
314 Kevin E. Noonan, Do Diagnostic Method Claims Fall under the Safe Harbor of 35 U.S.C. §
287(c)?, PATENTDOCS (Apr. 11, 2012, 11:07 PM), http://www.patentdocs.org/2012/04/do-diagnosticmethod-claims-fall-under-the-safe-harbor-of-35-usc-287c.html.
315 CANADIAN INTELLECTUAL PROPERTY OFFICE, MANUAL OF PATENT OFFICE PRACTICE §17.03.01
(Can.) (2017).
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are all outside of the scope of patent protection. Canada explicitly allows methods of
treatment for non-pathological conditions, such as aging and hair loss, and although
the EPO is not explicit in its allowance of such methods, has issued patents for methods
of treatment of non-pathological conditions.316
Despite disparate implementation measures and levels of detail on what exactly
counts as a method of therapy or surgery, the countries this Article studied are uniform
in their prohibition on patents on human medical methods. The United States and
Canada are unique among the countries studied in granting enforceable patents on
medical diagnostic testing methods for humans, although there is some public and
legal debate on whether this practice should continue.317 Although this debate could
go either way, the policy rationales behind banning therapeutic and surgical patents
seem to extend neatly to cover diagnostic methods, as innovations in diagnostic
methods “do not require the midwifery of patent law.”318 Therefore this Article argues
that, in the production of a new Article 27, diagnostic methods should join therapeutic
and surgical methods as unpatentable inventions in Canada and the United States.
Although this change would not be popular with the creators of diagnostic methods,
the expansion and harmonization of patent coverage in other areas throughout the
world would be sufficient tradeoff for the biotechnology industry to find the trade
palatable.
3. Animals
Even if a country prohibits patenting medical techniques on humans, does this
ban apply to patents on those same techniques in animals? This is a more difficult
policy question because there is public good that comes from increased agricultural
yield, and incentivizing innovation in the livestock sector would be a use of patent
policy. The countries studied in this Article have come to vastly different conclusions
on this question. India takes the strictest approach, excluding methods of diagnosis,
therapy, or surgery on non-humans, as well as methods that increase the economic
value of animals or their products. In contrast, Canada and Singapore exclude methods
of diagnosis, therapy, and surgery on animals, but hold that nontherapeutic methods
of increasing livestock productivity are patentable. The EPO likewise excludes such
medical methods on animals from patentability, but is silent on the issue of
nontherapeutic increasing of livestock productivity.
In contrast to these countries’ regimes, Japan and South Korea state that patents
on medical methods animals are allowable if humans explicitly disclaimed.319 The
United States, like medical methods for humans, has no prohibitions on patenting
medical methods for animals. Unlike human medical method patents though, there is
no parallel immunization of veterinarians like 35 USC § 287(c).
Therefore, like industrial applicability, the world has broken into two camps.
There is a strong moral argument that the treatment of human maladies shouldn’t be
European Patent No. 1,135,094 B1 (issued Nov. 3, 2009).
See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 72 (2012); see also
Noonan, supra note 314.
318 142 Cong. Rec. S12023 (1996) (Remarks of Senator Frist).
319 See supra Part II.D.III, II.E.4.
316
317
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an industrial enterprise, but the argument that the production of better, healthier,
more productive livestock is not a moral industry is weaker, given the historical
precedent.320 Farmers will always try to improve their livestock due to the economic
incentives to do so; the question countries must ask themselves is what form of
intellectual property protection should be offered for these improvements. If patents
are not offered on methods of medicine on animals, farmers will be incentivized to
utilize trade secret protection to maintain their competitive edge. Thus, the question
of animal medical method patents should be phrased as “does the disclosure mandated
by patents and the subsequent development of the science of the treatment of livestock
outweigh the marginal societal cost between the patent monopoly and the de facto
monopoly of keeping the innovation a trade secret.” This is the fundamental reason
that the patent system exists: society has judged the price paid to give a monopoly is
worth far less than the benefits received by follow-on innovation. In addition, followon innovation is not limited to animals: in countries that ban patents on human
medical methods, disclosed advances in animal medical methods can be utilized as a
starting point for innovations in human medicine. This benefit should more than
outweigh the marginal difference in costs between the patent monopoly and the trade
secret monopoly.
4. Plants and Animals Other Than Microorganisms
TRIPS Article 27(3)(b) allows countries to exclude plants, animals, and essential
biological processes for their production from patentability, but if a country will not
issue utility patent protection for plants it must have an effective sui generis system
for protecting innovations into plant varieties. Canada, the EPO, and India explicitly
exclude plants from utility patents and have a system of “plant patents,” whereas
Japan,321 South Korea,322 and Singapore323 do not explicitly exclude plants from
protection in their manuals of patent examining procedure, but have sui generis
systems for issuing “plant patents.” The treatment of plants is an area of relative
conformity in the policies implemented.
Canada, and India prohibit granting patents on animals or other multicellular
life. Japan, South Korea, Singapore, and the United States all permit patents on these
higher life forms so long as the other statutory requirements are met. The EPO grants
patents on transgenic animals by defining animal varieties to not encompass labcreated animals.324 There has been significant amounts of scholarship on whether
320 See, e.g., Amelie Scheu et al., The Genetic Prehistory of Domesticated Cattle from Their Origin
to the Spread Across Europe, 16 BMC GENETICS 15, 4 (2015).
321 See Muriel Lightbourne, Plants and Intellectual Property Rights in the US, Japan, and Europe,
IIP BULLETIN, https://www.iip.or.jp/e/e_summary/pdf/detail2004/e16_11.pdf (last visited Mar. 27,
2019).
322
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Mar. 27, 2019).
324 Bioethics and Patent Law: The Case of the Oncomouse, WIPO MAG. (June 2006),
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animal patents are worthwhile to society,325 but the general conclusion has been that
genetically modified animals are of such importance to research, and constitute such
a worthwhile inventive activity that patent protection should be granted. A revised
Article 27 should incorporate this understanding to provide worldwide protection for
the next generation of groundbreaking oncomouse326 development.
F. Other Exclusions
India is the only country that has express exceptions to patentability that go
beyond the enumerated categories in TRIPS. The Indian patent office explicitly
excludes methods of agriculture and horticulture from patentability.327 TRIPS Article
27(2) allows exclusions to patentability to protect human life, and India’s large
subsistence agricultural sector is a key factor in preventing widespread starvation on
the subcontinent. However, TRIPS does not allow an exclusion to patentability for lifesaving pharmaceutical compounds under 27(2). The second most prevalent cause of
death in India is diarrheal disease, a host of illnesses that can be treated by modern
medicine if it is available.328 India has granted patent protection to some of the most
promising ant diarrheal medications and not exempted them under 27(2).329 Although
malnutrition is the leading cause of death and disability in India,330 it would not be a
clear argument that advances in agricultural technology should be exempt from
patentability under 27(2) if clearly life-saving drugs are not.
The Indian Patent Office will not issue utility patents on the topography of
integrated circuits,331 but these designs are otherwise protected under the
Semiconductor Integrated Circuit Lay-out Designs Act of 2000.332 Like the parallel
tracks of design and utility patents in other countries, India has chosen to bifurcate its
patent laws, and if comparable protection is offered this would likely not be a violation
of TRIPS Article 27. However, the Integrated Circuit Lay-out Designs Act is a
registration system and not an examination system, and protection is limited to ten
years from filing.333 However, TRIPS Article 35 mandates countries provide protection
for integrated circuit topographies, but does not mandate that these protections fall
325 See, e,g., Elisabeth T. Jozwiak, Worms, Mice, Cows and Pigs: The Importance of Animal Patents
in Developing Countries, 14 NW. J. INT’L L. & BUS. 620 (1994); Rebecca Dresser, Ethical and Legal
Issues in Patenting New Animal Life, 28 JURIMETRICS 399 (1988).
326 Fiona Murray, Patenting Life: How the Oncomouse Patent Changed the Lives of Mice and Men,
in MAKING AND UNMAKING INTELLECTUAL PROPERTY: CREATIVE PRODUCTION IN LEGAL AND
CULTURAL PERSPECTIVE (Mario Biagioli, Peter Jaszi & Martha Woodmansee eds., 1st ed. 2011).
327 OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS, AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE § 08.03.05.07 (India) (2010).
328 Global Health – India, CDC, https://www.cdc.gov/globalhealth/countries/india/pdf/IndiaFactsheet-p.pdf (last visited Mar. 27, 2019).
329 India Patent No. 259137 (issued Feb. 27, 2014).
330 India, INSTITUTE FOR HEALTH METRICS AND EVALUATION, http://www.healthdata.org/india
(last visited Mar. 27, 2019).
331 OFFICE OF CONTROLLER GENERAL OF PATENTS, DESIGNS, AND TRADEMARKS, MANUAL OF
PATENT OFFICE PRACTICE AND PROCEDURE § 08.03.05.14 (India) (2010).
332 The Semiconductor Integrated Circuits Layout Design Act, (India) (2000), http://www.wipo.in
t/wipolex/en/text.jsp?file_id=128089 (last visited Mar. 27, 2019).
333 Id.
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under the umbrella of Article 27. Therefore, India’s sui generis system of protection
may be in compliance with its TRIPS obligations, even though such topographies are
carved out of utility patents.
IV. CONCLUSION: CURRENT DISPUTES AND POTENTIAL RESOLUTIONS
In the analysis of the manuals of patent examining procedure, this Article argues
that there are areas where TRIPS Article 27 needs to be either refined, applied, or
revised. First, the definition of industrial applicability needs to reflect the actual
practice of the majority of states, and to not bar non-commercial but useful inventions
from patenting. Second, member nations should strike the allowance for prohibiting
patents on non-human higher life forms. Third, TRIPS should be revised to include
specific permission for countries to set up sui generis patent systems for integrated
circuit topographies, similar to the current carve-out for plants. Fourth, TRIPS should
address the immunization against infringement of certain patents to restrict such
immunity to accomplish the aims of TRIPS. Finally, the international community
should pressure India to comply with its TRIPS obligations and issue patents on
methods of agriculture.
A. Harmonize the Interpretation of Industrial Applicability.
The exclusions to patentability under the guise of industrial applicability should
be harmonized to create uniform incentives for innovation. As discussed in Section III,
there are two primary camps in the understanding of what it means to be industrially
applicable. First, the United States, Canada, India, and Singapore all treat industrial
applicability as an extension of defining what counts as an invention - something has
to have some use to be truly called an “invention.” Japan and South Korea though
extend industrial applicability to a stand-alone requirement of commercial utility. This
focus on commerce unwisely excludes significant areas of technological innovation, and
a wise use of immunization for non-commercial infringement would minimize the harm
these patents could cause to research while still reaping the innovation incentives.334
Inventors should be the ones to decide if the potential commercial profits they can
capture exceed the costs of filing and enforcing their patent. The use of over-narrow
definitions of industrial applicability by Japan and South Korea go beyond enforcing
allowed exclusions to patentability, and reflect an overbroad view of what should not
be patented for the public good. These same protections can be served by immunizing
certain actors from infringement without excluding whole areas of technological but
non-commercial research from the patent apparatus.

334 See, e.g., Kevin Iles, A Comparative Analysis of the Impact of Experimental Use Exemptions
in Patent Law on Incentives to Innovate, 4 NW. J. TECH. & INTELL. PROP. 61, 63 (2005); Vihar R. Patel,
Are Patented Research Tools Still Valuable? Use, Intent, and A Rebuttable Presumption: A Proposed
Modification for Analyzing the Exemption from Patent Infringement Under 35 U.S.C. S 271(e)(1), 47
IDEA 407, 427 (2007); Alicia A. Russo & Jason Johnson, Research Use Exemptions to Patent
Infringement for Drug Discovery and Development in the United States, 5 COLD SPRING HARB.
PERSPECT. MED. 1 (2015).
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B. Non-human Higher Life Forms Should Be Patentable.
As argued earlier, Canada and India’s exclusion of higher life forms from
patentability is an outlier. There was significant debate over whether the Harvard
oncomouse was patentable at the turn of the century, but the Canadian Supreme Court
articulated that the public policy arguments could not overcome the language of the
statue.335 Sound public policy shows even more strongly now than it did in 2001 how
patents on genetically modified organisms promote useful research and development,
and most countries have recognized this. The prohibition against patenting higher life
forms is currently allowed by TRIPS, which was negotiated in the early years of viable
genetically modified higher life forms. A revision of TRIPS should reflect the new
understanding of the usefulness of genetically modified higher life forms. This will
require updating of national laws to draw the line between the newly patentable nonhuman, and the still universally unpatentable human higher life forms. Given the
consensus that humans should not be patentable, the updates required to ensure that
humans remain unpatentable should be politically palatable.
C. Specific Carve-Outs, Like Plant Patents for Functional Designs
India has a creative solution to the gap between utility patents and design patents
in providing a sui generis system of intellectual property protection for the functional
design of integrated circuit topographies. Traditional design patent law does not
protect such functional designs, but the innovation embodied in these inventions is
something worth capturing by the patent system to allow for disclosure and spur
follow-on innovations. The United States also attempted to implement a similar
system, although its effectiveness is in debate.336 Explicitly allowing for direct
protection on these designs in a sui generis system is a good way to reconcile some of
the problems shoehorning them into either design or utility patent systems would
cause, and is the path that countries are taking absent any international agreement.
Such a carve-out should be explicitly allowed by TRIPS for functional designs in order
to facilitate this expansion of intellectual property protection into the gap between
design and utility patents.
D. The Rules for Immunization Against Infringement Should Be Codified.
Imagine the United States felt like promising foreign solar panel technology was
being restricted by unpracticed patents. How could the United States encourage
commercialization? One option would be to cancel the patents and refuse to issue any
more patents on solar panel technology, a clear TRIPS violation. A second option, one

335 See Anwar N. Khan, Canadian Researchers and Patenting of Higher Life, 33 J.L. & EDUC. 63,
65-66 (2004).
336 See Leon Radomsky, Sixteen Years After the Passage of the U.S. Semiconductor Chip Protection
Act: Is International Protection Working?, 15 BERKELEY TECH. L.J. 1049 (2000).
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that is explored in depth elsewhere,337 is to force a compulsory license on the patent
holder, giving compensation, but freeing the technology for use. A third method of
accomplishing this goal is the parallel to the United States’ implementation of a ban
on medical method patents and research tool patents: immunize those most likely to
infringe from liability. This is not prohibited by TRIPS, and functions as a de facto
implementation of option one above.
However, as seen in the analysis of industrial applicability and the exclusion of
medical technologies, immunization against infringement can serve as an important
tool in national patent offices’ kit to promote innovation without restricting use of
technology for the public good. In the United States, if an inventor wants to pursue
research into transgenic organisms thinking that there will be additional uses outside
of the research tool context, society benefits if one is discovered via the commercial
exploitation — the benefits of which the inventor captures due to the patent — but also
benefits via the disclosure if a commercial application isn’t discovered. Contrast this
to the situation where an inventor knows that no patent will be issued until a
commercial use is identified — the inventor will keep the knowledge a trade secret out
of fear that they will not be able to get a patent later due to novelty concerns, if they
pursue the research at all. Therefore, immunization of key users gives national patent
offices the flexibility to grant patents that may otherwise hinder the development of
society, and gives inventors the agency to pursue research into possible dual-use
technologies.
While this strategy of patents plus immunization may be an ideal implementation
of allowed exclusions to patentability to allow inventors to capture any non-prohibited
subject matter on dual-use claims, it presents a significant opportunity of misuse.
Explicit language in TRIPS to prevent this workaround except in enforcement of
allowed TRIPS prohibitions would forestall any attempt to honor the law, but not the
spirit of TRIPS. This would still allow nations to have the freedom to shape their patent
law within the spirit of TRIPS, but not undercut the agreement.
E. Agriculture
India’s prohibition of agricultural method patents is unique and seems to
contradict Article 27(1)’s mandate that patents be “enjoyable without discrimination
as to . . . the field of technology.” This Article argues that this prohibition is also unwise
on policy grounds, as it discourages the dissemination of agricultural knowledge due
to the increased reliance on trade secrecy. Therefore, work needs to be done to bring
India into compliance with its TRIPS obligations for the good of agricultural research
and development, and by extension, the people relying on increases in food yield to
survive an increasing tumultuous climate.

337 See, e.g., Charlene A. Stern-Dombal, Tripping over Trips: Is Compulsory Licensing Under Ebay
at Odds with U.S. Statutory Requirements and Trips?, 41 SUFFOLK U. L. REV. 249, 250 (2007); Cole
M. Fauver, Compulsory Patent Licensing in the United States: An Idea Whose Time Has Come, 8 NW.
J. INT’L L. & BUS. 666, 667 (1988).

